DMK Pharmaceuticals Corporation (DMK)

Overview

DMK Pharmaceuticals Corporation is a clinical stage neuro-biotechnology firm focused on the development and commercialization of medical solutions for allergy, opioid overdose, respiratory, and inflammatory diseases. Originally known as Adamis Pharmaceuticals Corporation, it underwent a rebranding to DMK Pharmaceuticals Corporation in September 2023. With its headquarters in San Diego, California, the company has made significant strides in addressing critical areas in healthcare through innovative products. As of February 2, 2024, the company has filed for voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, reflecting challenges in its operational journey but also a step towards restructuring and potential recovery.

Products and Services

• DPI-125: This lead clinical stage product candidate by DMK Pharmaceuticals Corporation is designed for the treatment of opioid use disorder. DPI-125 represents the forefront of the company's efforts to combat the opioid crisis with a focus on neuro-biotechnological interventions.
• SYMJEPI (Epinephrine Injection): A crucial emergency treatment for those experiencing severe allergic reactions, SYMJEPI is used for the immediate treatment of allergic reactions to stinging and biting insects, foods, drugs, diagnostic testing substances, and other allergens. It also serves as a treatment option for idiopathic or exercise-induced anaphylaxis, highlighting its versatility in managing allergic emergencies.
• ZIMHI (Naloxone Injection): This product is targeted at reversing opioid overdoses, a critical aspect of responding to the opioid epidemic. ZIMHI embodies DMK Pharmaceuticals Corporation’s dedication to providing life-saving treatments in scenarios of opioid overdose, leveraging its expertise in pharmaceuticals to address a pressing public health issue.